广州维力医疗器械股份有限公司 章程 广州维力医疗器械股份有限公司 章程 （二〇二五年八月修订） 广州维力医疗器械股份有限公 司 章程 目 录 广州维力医疗器械股份有限公司 章程 第一章 总则 第一条 为维护公司、股东、职工和债权人的合法权益，规范公司的组织和 行为，根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人 民共和国证券法》（以下简称"《证券法》"）和其他有关规定，制定本章程。 第二条 广州维力医疗器械股份有限公司（以下简称"公司"）系经广州市 对外贸易经济合作局穗外经贸资[2011]482号《关于中外合资企业广州市韦士泰 医疗器械有限公司改制为外商投资股份制企业的批复》批准，由广州市韦士泰医 疗器械有限公司（系中外合资企业）整体变更设立的股份有限公司。在公司登记 管理机关注册登记，取得营业执照，公司统一社会信用代码为 广州市韦士泰医疗器械有限公司原有股东为公司发起人。 第三条 公司于2015年1月30日经中国证券监督管理委员会（以下简称"中国 证监会"）证监许可【2015】197号文核准，首次向社会公众公开发行人民币普通 股2500万股，于2015年3月2日在上海证券交易所上市。 第四 ...

Core Viewpoint - Guangzhou Pharmaceutical Co., Ltd. (referred to as "Guangzhou Medicine") will be listed on the National Equities Exchange and Quotations (NEEQ) starting May 20, 2025, after previously attempting an IPO in Hong Kong without success [1][2]. Group 1: Company Overview - Guangzhou Medicine, established in 1951, is the largest pharmaceutical distribution company in South China, engaging in wholesale and retail of pharmaceuticals, including Western medicine, traditional Chinese medicine, and medical devices, with over 1,700 employees [2]. - White Cloud Mountain Pharmaceutical Group Co., Ltd. (referred to as "White Cloud Mountain") holds a 90.92% stake in Guangzhou Medicine, making it the controlling shareholder [2]. Group 2: Financial Performance - Guangzhou Medicine's revenue for 2023 and 2024 is projected to be 52.591 billion yuan and 54.605 billion yuan, respectively, with net profits of 649 million yuan and 578 million yuan [2]. - In contrast, White Cloud Mountain reported a decline in net profit for 2024, reaching 2.835 billion yuan, a decrease of 30.09% year-on-year, with total revenue of 74.993 billion yuan, down 0.69% [4]. Group 3: Strategic Decisions - The decision to list Guangzhou Medicine on the NEEQ follows the termination of its H-share listing plans due to changes in market conditions and the expiration of regulatory approvals [2]. - White Cloud Mountain stated that the new listing will not adversely affect its financial status or operational results, as Guangzhou Medicine will remain a consolidated subsidiary [3]. Group 4: Challenges and Considerations - White Cloud Mountain's financial difficulties, including significant impairment provisions totaling approximately 471 million yuan, may impact Guangzhou Medicine's future fundraising efforts [5]. - The company faces challenges from industry policy changes and intense market competition, raising questions about its plans for product structure optimization and cost control [5].

Core Points - The company aims to manufacture high-quality medical supplies to promote human health and provide satisfactory economic benefits to investors [13] - The registered capital of the company is RMB 292.868018 million [6] - The company was approved for its initial public offering of 25 million shares on March 2, 2015, and is listed on the Shanghai Stock Exchange [3][4] Chapter Summaries General Provisions - The company is established as a joint-stock limited company based on the approval from the Guangzhou Foreign Trade and Economic Cooperation Bureau [2] - The company operates under the laws of the People's Republic of China, including the Company Law and Securities Law [1] Business Objectives and Scope - The business scope includes retail of medical supplies, manufacturing of medical plastic products, and various medical equipment [14] - The company is committed to high-quality production and enhancing human health [13] Shares - The total number of shares issued by the company is 292,868,018, all of which are ordinary shares [20] - The company adheres to principles of fairness and transparency in share issuance [16] Shareholders and Shareholder Meetings - Shareholders have rights to dividends, participate in meetings, and supervise company operations [33] - The company must hold annual shareholder meetings within six months after the end of the fiscal year [45] Voting and Resolutions - Ordinary resolutions require a simple majority, while special resolutions require two-thirds majority approval from attending shareholders [78][80] - Shareholders can propose agenda items for meetings, and the company must notify them of the meeting details in advance [56][57]